Aptatek BioSciences leverages DNA aptamer technology to build simple, quantitative point-of-care diagnostics for home use by patients with chronic conditions. Its lead product, PheCheck™, is an aptamer-based at-home monitor for phenylalanine levels and has received FDA breakthrough diagnostic device designation. The company announced bridge financing from strategic investor Canterbury Scientific to support ongoing clinical development and to accelerate commercialization. The funding is intended to advance clinical work and move the PheCheck platform closer to market availability for PKU patients. Canterbury Scientific is described as a leading global OEM supplier of IVD controls and remains a strategic partner in the program. Aptatek was founded as a spin-out from Columbia University and emphasizes patient-centric home monitoring solutions for chronic disease management. Aptatek BioSciences develops aptamer-based assay chemistry for point-of-care health testing in home settings, with an initial product enabling clinical-grade monitoring of phenylketonuria (PKU). The company is a Columbia University spinout and is positioned to replace slow, centralized lab testing with an easy-to-use portable device. The $4 million seed financing will fund development and clinical validation of the first product. Proceeds will also support key hires to expand the team. Aptatek is evaluating further applications in chronic kidney disease and medication management. The company emphasizes product manufacturing and global reach as part of its commercialization plans.

Total raised

$4M

Funding rounds

2

Latest round

Seed

Latest activity

Mar 2022